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There is increasing evidence that SARS-CoV-2 not only affects the respiratory tract but also impacts the CNS, resulting in neurological symptoms such as loss of smell and taste, head- ache, fatigue, nausea and vomiting in more than one-third of indi-viduals with COVID-19 (refs. 1,2). Moreover, acute cerebrovascular disease and impaired consciousness have been reported3. While 
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The newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a pandemic respira-
tory disease. Moreover, thromboembolic events throughout the body, including in the CNS, have been described. Given the 
neurological symptoms observed in a large majority of individuals with COVID-19, SARS-CoV-2 penetrance of the CNS is likely. 
By various means, we demonstrate the presence of SARS-CoV-2 RNA and protein in anatomically distinct regions of the naso-
pharynx and brain. Furthermore, we describe the morphological changes associated with infection such as thromboembolic 
ischemic infarction of the CNS and present evidence of SARS-CoV-2 neurotropism. SARS-CoV-2 can enter the nervous system 
by crossing the neural–mucosal interface in olfactory mucosa, exploiting the close vicinity of olfactory mucosal, endothelial and 
nervous tissue, including delicate olfactory and sensory nerve endings. Subsequently, SARS-CoV-2 appears to follow neuro-
anatomical structures, penetrating defined neuroanatomical areas including the primary respiratory and cardiovascular control 
center in the medulla oblongata.
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recent studies have described the presence of viral RNA in the brain 
and cerebrospinal fluid (CSF), they have lacked proof of genuine 
SARS-CoV-2 infection4,5. A systematic analysis of autopsy brains 
and peripheral tissues aimed at understanding the port of entry 
and distribution for SARS-CoV-2 within the CNS has therefore 
been missing6.
Currently, there are seven types of coronavirus (CoV) that nat-
urally infect humans7,8, and, of these, at least two endemic strains 
have been shown to enter and persist in the CNS. In one autopsy 
study, 48% of the investigated cases carried detectable human CoV 
RNA in the CNS9. Additionally, the neuroinvasive potential of 
SARS‐CoV and Middle East respiratory syndrome (MERS)-CoV, 
which are evolutionarily closely related to SARS-CoV-2, has previ-
ously been described10–12.
SARS-CoV, including SARS-CoV-2, are known to enter human 
host cells primarily by binding to the cellular receptor angioten-
sin‐converting enzyme 2 (ACE2) and by the action of the serine 
protease TMPRSS2 for spike (S) protein priming13. Supporting evi-
dence comes from animal studies demonstrating that SARS‐CoV 
is capable of entering the brain upon intranasal infection of mice 
expressing human ACE2 (refs. 12,14). In the lung, bronchial transient 
secretory cells express ACE2 and TMPRSS2 (ref. 15). Similarly, there 
is evidence for ACE2 expression in neuronal and glial cells in the 
human CNS16. In human olfactory mucosa, ACE2 was shown to be 
expressed by non-neuronal cells under physiological conditions17, 
while little is known about ACE2 expression in an inflammatory or 
septic setting18.
Because knowledge of SARS-CoV-2 neurotropism and potential 
mechanisms of CNS entry and viral distribution is key for a better 
understanding of COVID-19 diagnosis, prognosis and interven-
tional measures, we assessed olfactory mucosa, its nervous projec-
tions and several defined CNS regions in 33 individuals who died in 
the context of COVID-19.
Results
We analyzed the cellular mucosal–nervous micromilieu as a first 
site of viral infection and replication, followed by thorough regional 
mapping of the consecutive olfactory nervous tracts and defined CNS 
regions, in autopsy material from 33 individuals with COVID-19 
(n = 22 male and n = 11 female) examined between March and 
August of 2020 (Supplementary Tables 1 and 2). The median age at 
death was 71.6 years (interquartile range, 67–79 years; range, 30 to 
98 years), and the time from onset of COVID-19 symptoms to death 
ranged from 4 to 79 days, with a median of 31 days. Cases were not 
preselected with regard to clinical and/or neurological symptoms, 
which, owing to the pandemic situation, in some instances were not 
fully documented or not possible to retrieve. Clinically documented 
COVID-19-associated neurological alterations included impaired 
consciousness (n = 5), intraventricular hemorrhage (n = 2), head-
ache (n = 2) and behavioral changes (n = 2); acute cerebral ischemia 
was reported for 2 individuals, while neuropathological postmor-
tem workup revealed acute infarcts in 6 individuals (Supplementary 
Table 2). Coexisting conditions included diabetes mellitus (n = 4), 
hypertension (n = 21), cardiovascular disease (n = 9), hyperlipid-
emia (n = 2), chronic kidney disease (n = 2), prior stroke (n = 6) and 
dementia (n = 5) (Supplementary Table 1). Although all 33 individ-
uals required mechanical ventilation and at the time of autopsy were 
found to have suffered from COVID-19-associated lung disease, 9 
did not receive mechanical ventilation according to the will of the 
respective individual. Additional clinical information on comorbid-
ities is provided in Supplementary Table 1. Thirty-one individuals 
were proven to be positive by quantitative PCR with reverse tran-
scription (RT–qPCR) for SARS-CoV-2 before death (n = 31 of 33), 
while 2 individuals showed a clinical presentation highly suggestive 
of COVID-19 (n = 2 of 33). Correspondingly, ACE2 was detectable 
in olfactory mucosa by means of immunohistochemistry, while 
we found no reliable ACE2 immunoreactivity in the parenchyma 
of the CNS, namely, in the olfactory bulb and medulla oblongata 
(Supplementary Fig. 1).
Regional mapping of SARS-CoV-2 RNA in olfactory mucosa, its 
nervous projections and distinct CNS regions. Assessment of viral 
load by means of RT–qPCR in regionally defined tissue samples 
including the olfactory mucosa (R1), olfactory bulb (R2), olfactory 
tubercle (R3), oral mucosa (uvula; R4), trigeminal ganglion (R5), 
medulla oblongata (R6) and cerebellum (R7) demonstrated the 
highest levels of viral RNA for SARS-CoV-2 within the olfactory 
mucosa sampled directly beneath the cribriform plate (n = 20 of 
30; Fig. 1a). Lower levels of viral RNA were found in the cornea, 
conjunctiva and oral mucosa, highlighting the oral and ophthal-
mic routes as additional potential sites of SARS-CoV-2 CNS entry 
(Fig. 1b–d). In only a few COVID-19 autopsy cases, the cerebellum 
(n = 3 of 24) was positive for SARS-CoV-2 by means of RT–qPCR. 
The carotid artery wall served as a control tissue for excluding or 
proving systemic (vascular) entry routes to the CNS and was found 
to be negative in 12 of the 13 samples analyzed; the one positive 
result was derived from the carotid artery of an individual with 
acute COVID-19 disease. Subgenomic RNA (sgRNA) is used as a 
surrogate for active viral replication. We obtained a positive result 
in 4 of 20 olfactory mucosa samples positive for SARS-CoV-2 
RNA and 1 of 6 uvula samples positive for SARS-CoV-2 RNA, but 
in none of the other tissues analyzed in this study (Fig. 1b–d and 
Supplementary Table 2). Disease duration inversely correlated with 
the amount of detectable SARS-CoV-2 RNA in the CNS, with high 
SARS-CoV-2 RNA levels found in individuals with COVID-19 who 
had relatively short disease duration, whereas individuals with pro-
longed COVID-19 disease typically had low RNA load (correlation 
coefficient r = −0.5, **P = 0.006 from n = 29 individuals; Fig. 1e).
The olfactory mucosal–nervous milieu as a SARS-CoV-2 CNS 
entry-prone interface. Anatomical proximity of neurons, nerve 
fibers and mucosa within the oro- and nasopharynx (Fig. 2a–f) 
and the reported clinical–neurological signs related to alterations 
in smell and taste perception suggest that SARS-CoV-2 exploits 
this neural–mucosal interface as a port of entry into the CNS. The 
olfactory epithelium is organized as a pseudostratified epithelial 
structure mainly composed of olfactory sensory neurons (OSNs), 
apical sustentacular cells, Bowman’s gland (BG), microvillous cells 
and neural stem cells19. Horizontal basal cells (HBCs) and glo-
bose basal cells (GBCs) complete the spectrum of immature and 
mature neural/neuronal cells20,21. On the apical side of the olfactory 
mucosa, the dendrites of OSNs project into the nasal cavity, while 
on the basal side the axons of OSNs merge into fila, which pro-
trude through the cribriform plate directly into the olfactory bulb 
(Fig. 2), thereby also having contact with CSF22. OSNs are bipolar 
cells, and somatic (including dendritic and axonal) expression of 
olfactory membrane protein (OMP) indicates their mature state 
(Fig. 2g), while expression of class III β-tubulin (TuJ1) corresponds 
to both immature and mature neuronal cells within the olfactory 
mucosa20 (Fig. 2h). The neuronal cells coalesce with the other cells 
to the epithelial layer.
SARS-CoV-2 tropism within the olfactory mucosa. When assess-
ing the local distribution of SARS-CoV-2 within SARS-CoV-2 
PCR-positive tissue at the cellular level, we found that SARS-CoV S 
protein was most prevalent in the olfactory mucosa. Using immuno-
histochemistry, distinct immunoreactivity for SARS-CoV S protein, 
including a characteristic granular, partly perinuclear pattern, was 
found in morphologically distinct cell types indicative of neuronal/
neural origin (Fig. 3a). SARS-CoV-2 RNA was detectable in cells 
of the olfactory epithelium and in olfactory mucus by RNAScope 
in situ hybridization (ISH) in formalin-fixed and paraffin-embedded 
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(FFPE) samples (Fig. 3b). On the ultrastructural level, we were able 
to detect intact CoV particles in an individual with high viral RNA 
load and presence of sgRNA (Fig. 3c–f). Re-embedding of FFPE 
olfactory mucosa for electron microscopy (EM) allowed selec-
tive assessment of a tissue region with a strong SARS-CoV-2 RNA 
ISH signal (Fig. 3b). Characteristic CoV substructures within the 
respective cellular compartments were found as expected, including 
surface projections (spikes) and partially visible membrane enve-
lope as well as a heterogeneous and partly granular electron-dense 
interior due to the presence of ribonucleoprotein (RNP). Only 
subtle ultrastructural differences as compared to CoV-infected cell 
cultures were noted. These were clearly discernible from intrinsic 
cellular structures or artifacts and can be entirely explained by the 
FFPE re-embedding procedure23–28 (Supplementary Fig. 2).
To further pinpoint which cells within the olfactory mucosa har-
bor SARS-CoV-2, we performed colocalization studies using vari-
ous neuronal markers and SARS-CoV S protein, finding perinuclear 
SARS-CoV S protein immunoreactivity in TuJ1+ (Fig. 4a–d), neu-
rofilament 200 (NF200)+ (Fig. 4e–h) and OMP+ (Fig. 4i–l) neural/
neuronal cells in three individuals with COVID-19 where adequate 
tissue for this type of analysis was available; olfactory mucosa from 
two individuals without COVID-19 was used as a negative con-
trol and showed no immunoreactivity for SARS-CoV S protein in 
otherwise equally detectable TuJ1+ or OMP+ neural/neuronal cells 
(Supplementary Fig. 3g,h).
The results of the different approaches used to detect SARS-CoV-2 
including SARS-CoV S immunostaining, ISH for SARS-CoV-2 
RNA and ultrastructural analyses to visualize CoV particles at vari-
ous sites and regions are summarized in a heatmap-like manner 
(Fig. 5), ultimately supporting the hypothesis of a site-specific, local 
CNS infection by SARS-CoV-2.
The SARS-CoV-2-mediated neuroinflammatory response. As an 
indirect sign of local infection and ongoing inflammation, we looked 
for small cell clusters of early activated macrophages expressing 
myeloid-related protein 14 (MRP14), which were detected in the 
olfactory epithelium (Supplementary Fig. 1). These cells can initiate 
and regulate an immune cascade that, upon influenza virus infec-
tion, has been shown to act as an endogenous damage-associated 
molecular pattern (DAMP), ultimately initiating a virus-associated 
inflammatory response via TLR4–MyD88 signaling29. In the 
CNS, we found strong upregulation of human leukocyte antigen 
(HLA)-DR on microglia/macrophages, which were often arranged 
in so-called microglial nodules, in 13 of 25 individuals analyzed 
(Supplementary Table 2 and Supplementary Fig. 4b–f). There was 
no evidence of MRP14+ cells nor of infiltrating lymphomono-
cytic cells within the CNS. A correlate of this HLA-DR-positive, 
presumably myeloid-driven inflammatory response was found 
in the CSF, where levels of inflammatory mediators such as inter-
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Fig. 1 | Detection of SARS-CoV-2 in deceased individuals with COVID-19 in anatomically distinctly mapped oro- and nasopharyngeal as well as CNS 
regions. a, Cartoon depicting the anatomical structures sampled for histomorphological, ultrastructural and molecular analyses including SARS-CoV-2 
RNA measurement from fresh (non-formalin-fixed) specimens of deceased individuals with COVID-19. Specimens were taken from the olfactory mucosa 
underneath the cribriform plate (anatomical region R1, blue, n = 30), the olfactory bulb (R2, yellow, n = 31), the olfactory tubercle (R3, n = 7), different 
branches of the trigeminal nerve (including conjunctiva (n = 16) and cornea (n = 13)), mucosa covering the uvula (R4, n = 22), the respective trigeminal 
ganglion (R5, orange, n = 22), the cranial nerve nuclei in the medulla oblongata (R6, dark blue, n = 31), the cerebellum (R7, n = 24) and the carotid artery 
wall (n = 13). b–d, Quantitative data for each individual shown on a logarithmic scale normalized on 10,000 cells. e, Correlation of disease duration and 
viral RNA load in the CNS (typically measured in the olfactory bulb or medulla oblongata). The length of disease duration correlates inversely with the 
amount of detectable SARS-CoV-2 RNA (correlation coefficient r = −0.5, **P = 0.006 from n = 29 individuals). Females are represented by triangles and 
males are represented by circles; no data for P27 is shown because no viral testing could be performed on naive or cryopreserved tissue of P27.
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intercellular adhesion molecule-1 (sICAM-1) were found to be 
increased (Supplementary Fig. 4a)30.
Cerebral microthrombosis and acute CNS infarcts. In line with 
recent clinical data demonstrating thromboembolic CNS events in 
a few individuals with COVID-19 (ref. 31), we found in 18% of the 33 
individuals investigated (n = 6 of 33) a histopathological correlate 
of microthrombosis and subsequent acute territorial brain infarcts 
(Fig. 6a–c and Supplementary Table 2). Of note, there was increased 
immunoreactivity to SARS-CoV S protein (which is thought to also 
recognize other CoV types) in endothelial cells within these acute 
cerebral infarcts (Fig. 6b,c) in comparison to a weaker but similarly 
distributed endothelial staining pattern in some control individu-
als (Supplementary Fig. 5). Because of the limitations in obtain-
ing accessible and appropriate frozen, unfixed CNS tissue from 
these acute infarcts, we were only able to assess an infarct located 
within the medulla oblongata in one individual (P3) by means of 
RT–qPCR, finding that this sample was positive for SARS-CoV-2 
RNA. As shown for the CNS, microthromboembolic events were 
also detectable in the olfactory mucosa in one individual.
Discussion
Several recent tissue-based studies assessing CNS alterations in 
fatal COVID-19 have provided the first hints at histopathological 
changes occurring in COVID-19 such as hypoxia-related pathol-
ogy including CNS infarction due to cerebral thromboembolism 
and signs of a CNS-intrinsic myeloid cell response32–38 and/or 
have presented data on the presence of viral RNA in the CNS4,39. 
To extend existing knowledge and to provide further proof for the 
presence and distribution of SARS-CoV-2 in the olfactory mucosa 
and within the CNS, we visualized viral RNA and protein using 
ISH and immunohistochemical staining techniques. This allowed 
us to dissect the cells harboring the virus and shed light on the 
mechanism of SARS-CoV-2 CNS entry at the neural–muco-
sal interface in olfactory mucosa. We were also able to visualize 
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Fig. 2 | Close anatomical proximity of nervous and epithelial tissues in the olfactory mucosa. a–c, Cartoon (a) and histopathological coronal 
cross-sections (b,c; individual P9) depicting the paranasal sinus region with the osseous cribriform plate (turquoise asterisk and dotted line in b; pink 
asterisk and dotted line in c) and the close anatomical proximity of the olfactory mucosa (green in b, purple in c) and nervous tissue characterized by nerve 
fibers immunoreactive for S100 protein (c, brown). d, Cartoon representing the olfactory mucosa, which is composed of pseudostratified ciliated columnar 
epithelium (asterisk), basement membrane and lamina propria and also contains mucus-secreting BGs and bipolar OSNs, which coalesce to the epithelial 
layer. e,f, Immunohistochemical staining of the olfactory mucosa showing epithelial cells (e, immunoreactivity for the pan-cytokeratin marker AE1/AE3, 
red, individual P9), which closely intermingle with staining for OLIG2 specifying late neuronal progenitor cells and newly formed neurons  
(f, nuclear staining, brown, individual P27)45. In e, the basement membrane underneath the columnar AE1/AE3-positive epithelium is discontinued due to 
CD56-positive (brown) nerve fibers of either olfactory or trigeminal origin (arrow). g, Cell bodies (arrows) and dendrites (arrowheads) of OMP-positive 
mature OSNs (brown, control individual C6 without COVID-19) are shown. h, Immunostaining for TuJ1 corresponding to both immature and mature 
neural/neuronal cells and their dendrites (brown, control individual C6 without COVID-19). Scale bars: 0.5 cm (b,c), 30 µm (e,g,h) and 50 µm (f).
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misinterpreted40, especially when conclusions are solely based on 
relatively ill-defined virus-like substructures41. In tissues positive 
for SARS-CoV-2 RNA, we found SARS-CoV S protein in the cyto-
plasm of endothelial cells, in contrast to the findings of Solomon 
et al.38; the different results are most likely due to methodologi-
cal differences between the staining protocols used. The presence 
of SARS-CoV-2 in the CNS was found to result in a local CNS 
response mediated through HLA-DR+ microglia as effectors of 
a myeloid-driven inflammatory response. This innate immune 
response has a correlate in the CSF, where the levels of inflamma-
tory mediators were found to be increased.
Presence of intact CoV particles together with SARS-CoV-2 RNA 
in the olfactory mucosa, as well as in neuroanatomical areas receiv-
ing olfactory tract projections (Fig. 1b), may suggest SARS-CoV-2 
neuroinvasion occurring via axonal transport. However, morpho-
logical detection of single viral particles in axons is (if possible at all) 
very difficult owing to the very low number of viral particles that 
are expected, given that the viral reproduction apparatus is thought 
to be located in the neuronal somata. This difficulty in visualizing 
SARS-CoV-2 within the CNS on a cellular level is further aggra-
vated by the fact that the olfactory bulb is a relatively small CNS 
region with a limited number of neurons, which is evidenced by the 
small amount of viral RNA that was obtained in COVID-19 cases 
harboring SARS-CoV-2 PCR-positive olfactory bulbs. In addition, 
the ability to detect SARS-CoV-2 may also be affected by the dura-
tion of COVID-19 infection, as the duration determines the viral 
load at a given time point and location, and we cannot exclude the 
possibility that virus-infected (neuronal) cells might die and thus 
evade detection.
As we were able to detect SARS-CoV-2 RNA in some individu-
als in CNS regions that have no direct connection to the olfactory 
mucosa, such as the cerebellum, there may be other mechanisms 
or routes of viral entry into the CNS, possibly in addition to or 
in combination with axonal transport. For instance, migration of 
SARS-CoV-2-carrying leukocytes across the blood–brain barrier 
(BBB) or viral entry along CNS endothelia cannot be excluded. 
The latter is a valid possibility, at least in addition to a presumably 
axonal route, as we found immunoreactivity to SARS-CoV S pro-
tein in cerebral and leptomeningeal endothelial cells (Fig. 6b,c and 
Supplementary Fig. 5).
Widespread dysregulation of the cardiovascular, pulmonary and 
renal systems has been thought to be a leading cause of disease in 
severe or lethal COVID-19 cases42. In light of previous reports of 
infection by SARS-CoV and other CoVs in the nervous system43 
and our observations of SARS-CoV-2 in the brainstem, which com-
prises the primary respiratory and cardiovascular control center, it 
is possible that SARS-CoV-2 infection, at least in some instances, 
might aggravate respiratory or cardiac insufficiency—or even cause 
failure—in a CNS-mediated manner44. The presence of acute infarcts 
in the brainstem (n = 2 of 6 individuals analyzed; Supplementary 
Table 2) might support this notion. Even in the absence of clear 
signs of widespread distribution of SARS-CoV-2 in neuronal or glial 
cells of the CNS parenchyma in the COVID-19 autopsy cases inves-












Fig. 3 | Immunohistochemistry-, in situ hybridization- and electron microscopy-based detection of SARS-CoV within the olfactory mucosa. a, CoV 
antigen detected by anti-SARS-CoV S protein antibodies (brown, individual P30) exhibits a cytoplasmic, often perinuclear, signal for CoV-positive 
cells resembling epithelial cells and cells harboring dendrite-like projections (arrowhead) with tips (arrows), which morphologically qualify as OSNs. 
b, SARS-CoV-2 RNA ISH showing intense signals in the mucus layer and cells (arrows) of the epithelium (asterisk) (brown, individual P15). c–f, 
Ultrastructural images of re-embedded FFPE material showing numerous extracellular CoV particles (c, arrows) attached to kinocilia (c, white asterisks) 
and intracellular CoV particles (d–f, increasing magnification) in a ciliated cell (individual P15, punch biopsy from the area in b). In e and f, intracellular 
CoV particles are located within cellular compartments of different sizes and are similar in their size and substructure. In f, at high magnification, 
five particles in this region show a particularly well-recognizable substructure (black arrows) that includes characteristic surface projections (black 
arrowhead), a heterogeneous and partly granular electron-dense interior, most likely representing RNP (white arrowheads), and a membrane envelope 
(white arrows). Scale bars: 20 µm (a), 50 µm (b), 1 µm (c), 2 µm (d), 500 nm (e) and 200 nm (f).
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Fig. 4 | Colocalization of SARS-CoV spike protein with neural/neuronal cells in distinct olfactory mucosa samples from individuals with COVID-19. 
a–l, Representative maximum-intensity projections of confocal (a–d and i–l) or epifluorescence (e–h) microscopy images of olfactory mucosa showing 
intracytoplasmic staining for SARS-CoV S protein within TuJ1+ (a–d, individual P27), NF200+ (e–h, individual P27) and OMP+ (i–l, individual P27)  
OSNs. Staining for TuJ1, NF200 and OMP (magenta, Alexa Fluor 488) marks cells of neuronal origin, staining for SARS-CoV S protein (yellow,  
Alexa Fluor 555) visualizes the presence of SARS-CoV and DAPI staining (petrol) identifies all cell nuclei (n = 3 individuals with COVID-19  
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Fig. 5 | Summary of various SARS-CoV detection measures in deceased individuals with COVID-19. Various SARS-CoV-related investigations of the 
individuals who tested positive for SARS-CoV-2 by RT–qPCR in the olfactory mucosa (OM), the CNS or both. SARS-CoV-2 RT–qPCR positivity was 
combined with results derived from SARS-CoV-specific immunohistochemistry (IHC) and ISH as well as EM in appropriate tissue as available.
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vascular damage and allow the virus to spread more widely to other 
brain regions over time, thus eventually contributing to a more 
severe or even chronic disease course, depending on various fac-
tors such as the duration of viral persistence, viral load and immune 
status, among others.
Taking our findings together, we provide evidence that 
SARS-CoV-2 neuroinvasion can occur at the neural–mucosal inter-
face by transmucosal entry via regional nervous structures. This 
may be followed by transport along the olfactory tract of the CNS, 
thus explaining some of the well-documented neurological symp-
toms in COVID-19, including alterations of smell and taste percep-
tion. One caveat to note with the COVID-19 cases reported here is 
the relatively long postmortem interval, an almost insurmountable 
obstacle in autopsy studies, especially when performed under the 
emergency-like conditions encountered during a pandemic situa-
tion. Analysis of these samples is limited by well-known restrictions 
resulting from autolysis of cells and tissues, ultimately complicat-
ing the interpretation of morphological and molecular analyses. In 
spite of these limitations, we were able to retrieve numerous valu-
able insights. These included the detection of well-preserved CoV 
particles at the ultrastructural level in an individual with an 82-hour 
postmortem interval (P15) and important pathogenetic insights, 
thus enabling further, more detailed and mechanistic investigations 
while encouraging further autopsy studies including broad sam-
pling to allow multiple complementary analyses and the application 
of state-of-the-art methodologies. Such studies will allow identifica-
tion of the precise cellular and molecular SARS-CoV-2 entry mech-
anism as well as receptors on OSNs, where non-neuronal pathways 
may also have a role17.
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Fig. 6 | Signs of (micro)thromboembolic events and SARS-CoV-2 immunostaining in the CNS of deceased individuals with COVID-19. a, Hematoxylin 
and eosin (H&E)-stained FFPE section of the thalamus obtained from a deceased individual with COVID-19 (individual P26). Several small vessels exhibit 
fresh thrombi (pink, indicated by arrows) resulting in a large infarct of surrounding CNS tissue characterized by a substantial reduction of detectable 
neuronal and glial nuclei, edema and vacuolation. b,c, SARS-CoV S protein observed in the endothelial cells of small CNS vessels. Tissue with no obvious 
ischemic damage exhibits only sparse staining intensity in endothelial cells (b, medulla oblongata, n = 3 of 6; red, indicated by arrows, individual P3) when 
compared to endothelial cells within acute infarct areas (c, pons, n = 3 of 4; red, indicated by arrows, individual P4; inset depicts a magnified vessel from a 
different region of the same specimen exhibiting SARS-CoV S protein deposits within endothelial cells). Scale bars: 30 µm (a), 50 µm (b), 200 µm (c) and 
40 µm (inset in c).
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Methods
Study design. Thirty-three deceased individuals with COVID-19 either confirmed 
by PCR for SARS-CoV-2 (n = 31 of 33) or with clinical features highly suggestive 
of COVID-19 (n = 2 of 33) were included (Supplementary Table 1). Individuals 
were not preselected with regard to their clinical symptoms. Autopsies were 
performed at the Department of Neuropathology and the Institute of Pathology, 
Charité–Universitätsmedizin Berlin (n = 25 of 33), including one referral from 
the Institute of Pathology, DRK Kliniken Berlin, the Institutes of Pathology and 
of Neuropathology, University Medical Center Göttingen (n = 6 of 33) and the 
Institute of Forensic Medicine, Charité–Universitätsmedizin Berlin (n = 1 of 33). 
This study was approved by the local ethics committees (Berlin: EA1/144/13, 
EA2/066/20 and EA1/075/19; Göttingen: 42/8/20) as well as by the Charité–BIH 
COVID-19 research board and was in compliance with the Declaration of Helsinki; 
autopsies were performed on the legal basis of §1 of the Autopsy Act of the 
state Berlin and §25(4) of the German Infection Protection Act. In all deceased 
individuals, a whole-body autopsy was performed, which included a thorough 
histopathological and molecular evaluation comprising virological assessment 
of SARS-CoV-2 RNA and/or SARS-CoV S protein levels in the carotid artery, 
cornea, conjunctiva, optic nerve, uvula, olfactory mucosa, olfactory bulb, olfactory 
tract, trigeminal ganglion, medulla oblongata and cerebellum as indicated in 
Supplementary Table 2. To exclude cross-contamination, clean instruments for 
the preparation and sampling of each organ and region were always used. All 
individuals with COVID-19 with known disease duration and available PCR-tested 
appropriate CNS tissue were included (n = 29 of 33) to calculate the correlation 
coefficient for the correlation between disease duration and CNS SARS-CoV-2 
viral load. Therefore, we could not perform randomization as all individuals 
with SARS-CoV-2 RNA were included in the COVID-19 group and controls 
were defined as individuals negative for SARS-CoV-2 by PCR. Where available, 
clinical records were assessed thoroughly for preexisting medical conditions and 
medications and progression of the disease as well as COVID-19-related symptoms 
before death, with a special focus on neurological symptoms including alterations 
in olfaction and taste.
SARS-CoV- and SARS-CoV-2-specific PCR including subgenomic RNA 
assessment. For PCR-based assessment of SARS-CoV-2 RNA, unfixed and, where 
possible, non-cryopreserved (i.e., native) tissue samples were used. RNA was 
purified from ∼50 mg of homogenized tissue obtained from all organs by using the 
MagNAPure 96 system and the MagNAPure 96 DNA and Viral NA Large Volume 
kit (Roche) according to the manufacturer’s instructions.
Quantitative real-time PCR for SARS-CoV-2 was performed on RNA extracts 
with RT–qPCR targeting the SARS-CoV-2 E gene. Quantification of viral RNA was 
performed using photometrically quantified in vitro RNA transcripts as described 
previously46. Total DNA was measured in all extracts by using the Qubit dsDNA 
HS Assay kit (Thermo Fisher Scientific). The RT–qPCR analysis was replicated at 
least once for each sample.
Detection of sgRNA, as a correlate of active virus replication in the tested 
tissue, was performed by using oligonucleotides targeting the leader transcriptional 
regulatory sequence and a region within the sgRNA encoding the SARS-CoV-2 E 
gene, as described previously47.
Histological and immunohistochemical techniques. FFPE tissue blocks were 
taken at the day of autopsy when the postmortem interval was shorter than 24 h 
and fixed for 24 h in 4% paraformaldehyde. Otherwise, brain tissue was fixed 
for 14 d in 4% paraformaldehyde before cutting. Routine histological staining 
(H&E, Masson–Goldner, periodic acid–Schiff (PAS) reaction and toluidine 
blue) was performed according to standard procedures. Immunohistochemical 
staining was performed either on a Benchmark XT autostainer (Ventana Medical 
Systems) with standard antigen retrieval methods (CC1 buffer, pH 8.0, Ventana 
Medical Systems) or manually using 1-μm- or 4-μm-thick FFPE tissue sections. 
The following primary antibodies were used: polyclonal rabbit anti-S100 (Dako, 
Z0311; 1:3,000), monoclonal mouse anti-AE1/AE3 (Dako, M3515; 1:200), 
monoclonal mouse anti-MRP14 (Acris, BM4026B; 1:500, pretreatment protease), 
monoclonal mouse anti-CD56 (Serotec, ERIC-1; 1:200), mouse monoclonal 
anti-SARS spike glycoprotein (Abcam, ab272420; 1:100), goat anti-OMP 
(Wako, 019-22291; 1:1,000), rabbit monoclonal anti-βIII tubulin (Abcam, 
ab215037; 1:2,000), rabbit polyclonal anti-NF200 (Sigma, N4142; 1:100), rabbit 
polyclonal anti-ACE2 (Proteintech, 21115-1-AP; 1:3,000) and rabbit polyclonal 
anti-OLIG2 (IBL, 18953; 1:150, pretreatment Tris-EDTA + microwave). Briefly, 
primary antibodies were applied and developed by using either the iVIEW DAB 
Detection kit (Ventana Medical Systems) and the ultraView Universal Alkaline 
Phosphatase Red Detection kit (Ventana Medical Systems) or manual application 
of biotinylated secondary antibodies (biotinylated donkey anti-sheep-goat (1:200; 
Amersham, RPN 1025), biotinylated donkey anti-rabbit (1:200), biotinylated 
sheep anti-mouse (1:200; Amersham, RPN 1001), rabbit immunoglobulin 
(RPN1004), peroxidase-conjugated avidin and diaminobenzidine (DAB; Sigma, 
D5637) or 3-amino-9-ethylcarbazol (AEC). Sections were counterstained with 
hematoxylin, dehydrated in a graded alcohol and xylene series, mounted and 
coverslipped. Immunohistochemistry sections were evaluated by at least two 
board-certified neuropathologists with concurrence. To biologically validate all 
immunohistological staining, control tissues harboring or lacking the expected 
antigens were used. Staining patterns were compared to expected results as 
specified in the Supplementary Information (Supplementary Fig. 1a–d  
(ACE2), Supplementary Fig. 5e (SARS-CoV S), Supplementary Fig. 6 (NF200, 
SARS-CoV S) and Supplementary Fig. 3 (S100, OLIG2, HLA-DR, CD56, CD45, 
AE1/AE3, OMP and TuJ1)).
For immunofluorescence, the protocol was adapted as follows: Alexa  
Fluor 488-conjugated goat anti-rabbit (1:100; Jackson, 111515003) and Alexa 
Fluor 555-conjugated goat anti-mouse (1:100; Invitrogen) were used as secondary 
antibodies. Nuclei were counterstained with DAPI (Invitrogen, D3571),  
and sections were subsequently mounted on slides with Dako mounting  
medium (S3023).
SARS-CoV S immunohistochemistry and immunofluorescence. 
Immunohistochemical staining with mouse monoclonal anti-SARS spike 
glycoprotein antibodies (clone 3A2, ab272420, Abcam, 1:100) was performed  
using 1-μm-thick FFPE tissue sections. Slides were cooked in sodium citrate 
(pH 6.0; 95–100 °C) for 20 min, followed by enzymatic antigen retrieval with  
Triton X-100 and hydrogen peroxide for 15 min. Slides were blocked with 10% 
normal goat serum. Primary antibody (1:100, diluted in ProTaqs Antibody  
Diluent for IHC (Quartett) with 10% normal goat serum) was applied, and samples 
were incubated overnight. Then, secondary antibody (Biotin-SP-AffiniPure  
Goat Anti-Mouse IgG (H+L), Jackson ImmunoResearch Laboratories), diluted 
1:100 in ProTaqs Antibody Diluent for IHC, was applied, and samples were 
incubated for 2 h. Next, Streptavidin-HRP Reagent (RE7104, Leica Biosystems)  
and DAB substrate–chromogen (Agilent) were applied according to the 
manufacturer’s instructions. Slides were rinsed, counterstained with hematoxylin, 
dehydrated and mounted.
Staining signals were compared to those of non-COVID-19 control 
samples with respect to the staining intensity and staining pattern as specified 
in the Supplementary Information (Supplementary Fig. 5a–d; SARS-CoV S, 
Supplementary Table 2).
Image acquisition and processing. For fluorescence microscopy, an Olympus BX63 
(DP80 camera) automated fluorescence microscope was used, if not specified 
otherwise, for confocal images. For confocal microscopy, fluorescence signals were 
collected with an Olympus FluoView FV1000 confocal microscope using a ×60 
oil-immersion objective. For post‐acquisition image processing, the image analysis 
software Fiji was used48. For data handling of whole-slide images, an OME-TIFF 
workflow was used49.
Electron microscopy. Autopsy tissues were fixed with 2.5% glutaraldehyde 
in 0.1 M sodium cacodylate buffer, postfixed with 1% osmium tetroxide in 
0.05 M sodium cacodylate, dehydrated using a graded acetone series and then 
infiltrated and embedded in Renlam resin. Block-contrasting with uranyl acetate 
and phosphotungstic acid was performed at the dehydration step with 70% 
acetone. 500-nm semithin sections were cut using an ultramicrotome (Ultracut 
E, Reichert-Jung) and a Histo Jumbo diamond knife (Diatome), transferred onto 
glass slides, stretched at 120 °C on a hot plate and stained with toluidine blue at 
80 °C. 70-nm ultrathin sections were cut using the same ultramicrotome and 
an Ultra 35° diamond knife (Diatome), stretched with xylene vapor, collected 
onto pioloform-coated slot grids and then stained with lead citrate. Standard 
transmission EM was performed using a Zeiss 906 microscope in conjunction 
with a 2k CCD camera (TRS). Large-scale digitization was performed using a 
Zeiss Gemini 300 field-emission scanning electron microscope in conjunction 
with a STEM detector via Atlas 5 software at a pixel size of 4–6 nm. Regions of 
interest from the large-scale datasets were saved by annotation (‘mapped’) and then 
recorded at very high resolution using a pixel size of 0.5–1 nm.
Alternatively, ultrastructural analysis was performed from FFPE tissues.  
For virus detection, we took 3-mm punch biopsy cylinders from 
paraffin-embedded tissue. The respective regions were selected on the basis of 
the SARS-CoV ISH or immunohistochemistry signal. After deparaffinization 
in xylene, samples were rehydrated and postfixed in 1% formaldehyde and 2.5% 
glutaraldehyde in 0.05 M HEPES buffer (pH 7.2) for a minimum of 2–4 h at room 
temperature. Postfixation, block contrasting (tannic acid, uranyl acetate) and 
embedding in epon resin were performed according to a standard protocol50. 
Ultrathin sections were analyzed using a transmission electron microscope 
operated at 120 kV (Tecnai Spirit, Thermo Fisher), and images were recorded  
using a CCD camera (MegaviewIII, EMSIS).
Cytokine array. To analyze cytokine levels in CSF samples from deceased 
individuals with COVID-19 and controls (each n = 4), a human cytokine array 
(Bio-techne) was used according to the manufacturer’s instructions27. We analyzed 
all CSF samples from individuals with COVID-19 accessible at the time of analysis. 
This assay enables the semiquantitative measurement of 36 cytokines and related 
proteins (CCL1, CCL2, MIP-1α, CCL5, CD40L, C5/C5a, CXCL1, CXCL10, 
CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, 
IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, IL-13, IL-16, IL-17A, IL-17E, IL-18, IL-21, 
IL-27, IL-32a, MIF, serpin E1, TNF-α, TREM-1). Twelve of these 36 cytokines 
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were above the detection limit in our samples. Using the software Kodak D1 3.6 
(Eastman Kodak), a semiquantitative analysis was performed by determining the 
background-corrected sum intensity for each region of interest on the membrane. 
Separate membranes were normalized to each other using the results for the 
positive controls. We could not perform a statistical test owing to the limited access 
to sufficient CSF samples. Data represent single data points and the mean, range 
and 25th and 75th percentiles.
In situ hybridization. For detection of mRNA, the RNAScope 2.5 HD Reagent 
Kit-BROWN (ACD Europe SRL) was used. Briefly, paraffin sections were freshly 
cut, dried for 1 h at 60 °C and dewaxed before mild unmasking with Target 
Retrieval buffer and protease. Pretreated sections were hybridized with specific 
probes to Ppib as a positive control and irrelevant probe to dapβ as a negative 
control (both ACD Europe SRL). Virus-specific probe V-ncoV2019-S (ACD 
Europe SRL) was used for samples from individuals with COVID-19 and was 
accompanied by an additional slide with FFPE lung tissue from an individual 
with COVID-19 (P15) as a further positive control. After hybridization signal 
amplification, binding of probes was visualized with DAB. Nuclei were stained with 
hematoxylin, and sections were coverslipped with Ecomount.
Images were acquired using an AxioImager Z1 microscope (Carl Zeiss 
MicroImaging).
Statistics and reproducibility. All statistical analyses were performed and all 
graphs were created in GraphPad Prism 8 (GraphPad Software). No statistical 
methods were used to predetermine sample sizes; sample sizes in the current 
study are similar to those in previous COVID-19 autopsy reports by others4,32,38. 
We included all individuals with COVID-19 and material that were available 
as specified in the description of study design. The RT–qPCR analysis was 
replicated at least once for each positive sample. We did not exclude any data 
points from the performed analyses. To compute correlation between disease 
duration and viral load, Spearman nonparametric correlation was used. A 
two-tailed P value was calculated. Values were considered to be significant at 
P < 0.05. Statistical details for each analysis (for example, n, P and r values) are 
mentioned in each figure legend or in the respective part of the text. Owing to 
the nature of the investigation, data collection and analyses could not always 
be done in a blinded fashion. Histological staining, immunohistochemistry, 
immunofluorescence, ISH and EM results were analyzed independently  
by various neuropathologists in two distinct neuropathological institutions 
(Berlin and Göttingen) for each individual, region and specific staining/method. 
Histological staining, immunohistochemistry, immunofluorescence and  
ISH analyses were replicated at least once. EM was performed in one individual. 
The representative micrographs shown were adjusted in brightness and  
contrast to different degrees (depending on the need resulting from the  
range of brightness and contrast of the raw images), rotated and cropped in 
Adobe Photoshop.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated and/or analyzed during the current study are available from 
the corresponding author on reasonable request. The three electron microscopy 
datasets in Supplementary Fig. 2 are available for open access pan-and-zoom 
analysis at http://www.nanotomy.org/.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size all COVID-19 patients that died and recieved an autopsy were analyzed (N=33)
Data exclusions no data was excluded
Replication The SARS-CoV-2 qRT-PCR analysis was replicated at least once for each positive sample. All attemps were successful. SARS-spike protein 
immunostaining replicated once for all PCR positive samples (olfactory mucosa n= 10; CNS n= 8). All attemps were successful. In situ 
hybridisation was replicated once. All attemps were successful. Histological stainings, immunochistochemistry, and immunofluorescence, in-
situ hybridisation were replicated once. All attemps were successful. Electronmicroscopy was replicated once.  All attemps were successful. 
Histology, immunohistochemistry, immunofluorescence, and in-situ hybridization  were analyzed independently by various neuropathologists 
in two distinct neuropathological institutions (Berlin and Göttingen) for each patient, region and specific staining/method. 
Randomization We determined an infection with SARS-CoV2 by qRT-PCR. The patients were not randomized but assigned to either the SARS-CoV2 positive or 
negative group.
Blinding The investigators who performed SARS-CoV2 qRT-PCR and the histological/immunohistochemical/in-situ hybridizytion studies were blinded 
for the SARS-CoV-2 status of the patient.  
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems




Animals and other organisms
Human research participants
Clinical data
Dual use research of concern
Methods





Antibodies used The following primary antibodies were used:  
- polyclonal rabbit anti-S100 (Supplier: Dako, Catalog: Z0311, Target: Protein S100-A1, 1:3000) 
- monoclonal mouse anti-AE1/AE3 (Supplier: DAKO, Catalog: M3515, Clone:  AE1/AE3, 1:200) 
- monoclonal mouse anti-MRP14 (Supplier: Acris, Catalog: BM4026B, Clone: S36.48, 1:500) 
- monoclonal mouse anti-CD56 (Supplier: Serotec, Catalog: MCA 591, Clone: ERIC-1, 1:200) 
- mouse monoclonal anti-SARS spike glycoprotein antibody (Supplier: Abcam, Catalog: ab272420, Clone: 3A2, 1:100) 
- polyclonal goat anti-olfactory marker protein (OMP) (Supplier: Wako Chemicals USA, Catalog: 019-22291) 
- rabbit monoclonal anti-beta III tubulin (Supplier: Abcam, Catalog: ab215037, Clone: EPR19591) 
- rabbit polyclonal anti-neurofilament 200 (NF200) (Supplier: Sigma, Catalog: N4142) 
- rabbit polyclonal anti ACE2 (Supplier: Proteintech, Catalog: 21115-1-AP) 
- rabbit polyclonal anti-OLIG2 (Supplier: IBL America, Catalog: 18953, 1:150).  
Briefly, primary antibodies were applied and developed either using the iVIEW DAB Detection Kit (Supplier: Ventana Medical Systems, 
Catalog Number: 760-091) and the ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems, Catalog 
Number: 760-501) or by manual application of biotinylated secondary antibodies (biotinylated donkey anti-sheep/goat (1:200 
Company: Amersham, Catalog: RPN 1025), biotinylated donkey anti-rabbit (1:200), biotinylated sheep anti-mouse (1:200, Company: 
Amersham, Catalog: RPN 1001), rabbit Ig (Company: Amersham, Catalog: RPN1004), peroxidase-conjugated avidin, and 



















Validation To biologically validate all immunohistological stainings, control tissues with known expression pattern harboring or lacking the 
expected antigens were used (Supplemantary Figure 3). Immunohistochemical staining for S100 protein within normal (non-
diseased) autopsy brain tissue depicts glial cells such as astrocytes and neurons, while endothelial cells are spared. The positive 
control tissue for Olig2, which is known to show nuclear immunoreactivity in glioma tumor cells, while endothelial cells are not 
reactive to Olig2. HLA-DR immunoreactivity in the brain even under non-pathologic conditions is typically found on CNS-intrinsic 
myeloid cells, namely microglia, while e.g. neural/neuronal cells show no positivity for HLA-DR. All neuroepithelial cells in the CNS 
demonstrate a strong immunoreactivity for CD56, which cannot be found on endothelial cells. Tonsils were used to serve as positive 
control tissue for the general leukocyte marker CD45, while connective tissue of the capsula is not stained. The epithelium in a non-
diseased skin sample shows strong immunoreactivity for the pan-cytokeratin marker AE1/3 in contrast to the surrounding connective 
tissue. The nasal respiratory mucosa of a non-COVID-19 autopsy case – in contrast to the olfactory mucosa - lacks Tuj1+ and OMP+ 
neural/neuronal cells;  
In Supplementary Figure 5 we show validation of mouse monoclonal anti-SARS spike glycoprotein antibody  we used as positive 
control SARS-CoV-2-PCR+ mucosa, negative control was mucosa of SARS-CoV-2-PCR-negative cases. 
In Supplementary Figure 1 we show valdiation of rabbit polyclonal anti ACE2 (Proteintech, 21115-1-AP) the positive control proximal 
tubulus in kidney and negative control was brain parenchyma. 
 
All antibodies were checked for reproducability and integrety of the assay three times in independent staining experiments and in at 
least three different positive samples and compared to expected staining patterns in the controls regarding published expression of 
the antigens were applicable. Furthermore, an additional secondary-only antibody control (i.e. omission of first antibody) was 
performed for every setup. 
Human research participants
Policy information about studies involving human research participants
Population characteristics The  median  age at  death was 71.6 years (IQR: 67 - 79, range: 30 to 98 years), and the time from onset of COVID-19  
symptoms  to  death  ranged  from  4  to  79  days,  with  a  median  of  31  days.  Cases were not preselected with regard to 
clinical and/or neurological symptoms, which due to the pandemic situation in some instances were not fully documented or 
not possible to retrieve.  Clinically documented COVID-19-associated neurologic alterations were impaired consciousness 
(N=5 patients), intraventricular hemorrhage (N=2), headache (N=2) and behavioral changes (N=2); acute cerebral ischemia 
was reported for 2 patients, while neuropathological postmortem workup revealed acute infarcts in 6 patients 
(Supplementary Table 2). Coexisting conditions included diabetes mellitus (N=4), hypertension (N=21), cardiovascular disease 
(N=9), hyperlipidemia (N=2), chronic kidney disease (N=2), prior stroke (N=6), and dementia (N=5) (Supplementary Table 1). 
Although all 33 patients required mechanical ventilation and at time of autopsy suffered from COVID-19-associated lung 
disease, nine did not receive mechanical ventilation due to the respective patients’ will. a
Recruitment not applicable/see above
Ethics oversight This study was approved by the local Ethics Committee (Berlin: EA 1/144/13, EA2/066/20 and EA1/075/19 and Göttingen: 
42/8/20) 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
